ERBB2 and breast cancer: CAPItello-291 was a phase-3 trial that studied the effectiveness and safety of capivasertib vs. fulvestrant in HR-positive, HER2-negative breast cancer patients who had received AI treatment with or without CDK 4/6 inhibitors.